Aimmune Therapeutics Appoints Scientific Advisory Board of World-Renowned Food Allergy Experts

— Five Leading Food Allergy Researchers and Clinicians Form
Distinguished Board —

BRISBANE, Calif.–(BUSINESS WIRE)–Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing CODIT™ (Characterized Oral Desensitization
ImmunoTherapy) treatments for life-threatening food
allergies, today announced the membership of its Scientific Advisory
Board, comprised of internationally recognized food allergy experts.

The Scientific Advisory Board members and their academic affiliations

  • Dr. Kirsten Beyer, University Hospital Charité, Berlin, Germany
  • Dr. A. Wesley Burks, University of North Carolina, Chapel Hill
  • Dr. Thomas Casale, University of South Florida, Tampa
  • Dr. Jonathan Hourihane, University College Cork, Ireland
  • Dr. Stacie Jones, University of Arkansas for Medical Sciences, Little

“As we carry out our Phase 3 PALISADE trial and prepare to start the
RAMSES and ARTEMIS trials for AR101 for the treatment of peanut allergy,
we are seeking critical peer review of our upcoming development-stage
programs from these expert research physicians,” said Daniel Adelman,
M.D., Chief Medical Officer of Aimmune. “Their experienced,
evidence-based critique will help us in the planning and optimization of
forthcoming clinical trials, development strategy and selection of our
future therapeutic targets.”

All of the members of Aimmune’s Scientific Advisory Board are
investigators in PALISADE, Aimmune’s current Phase 3 clinical trial of
AR101 for the treatment of peanut allergy. AR101 is Aimmune’s biologic
oral immunotherapy for desensitization of patients with peanut allergy.

“Throughout our clinical trials, we have had the good fortune to work
with many dedicated and insightful allergists, and we look forward to
continuing to benefit from their knowledge and experience. We are
delighted to establish a formal review structure with this group of
exceptional researchers, who together have contributed so much to
advancing the field of food allergy,” said Aimmune CEO Stephen Dilly,
M.B.B.S., Ph.D. “Our PALISADE trial gave us the opportunity to expand
our clinical activity in both the United States and Europe and work
directly with Dr. Casale, Dr. Beyer and Dr. Hourihane, each of whom has
informed our perspective on critical issues. Dr. Burks and Dr. Jones, of
course, have been invaluable guides during not only our current and
earlier clinical trials, but also during the foundation of our company
itself, as they generously provided data that formed the foundation of
our AR101 program. We are truly grateful to have the support of all of
these physicians as we pursue our global development programs aimed at
improving the lives of people with food allergies.”

Kirsten Beyer, M.D., is a Professor in the Department of Pediatric
Pneumology and Immunology at University Hospital Charité in Berlin. Her
research experience spans the spectrum of pediatric allergy, with a
focus on food allergy. Her interests include food allergy prevention,
diagnosis and treatment. Currently, her group is studying the induction
of oral tolerance through oral immunotherapy in food-allergic children
and the primary prevention of hen’s egg allergy through early hen’s egg
feeding, among other studies. She is also part of the EU-funded food
allergy project EuroPrevall, studying a European birth cohort of more
than 12,000 babies, which will be re-evaluated at school age within the
EU-funded project iFAAM. Dr. Beyer qualified as an M.D. at the Free
University in Berlin, Germany, and carried out her pediatric training
and fellowship at the Humboldt University in Berlin. She was also a
visiting scientist at Johns Hopkins University and an Assistant
Professor of Pediatrics at Mount Sinai School of Medicine.

A. Wesley Burks, M.D., is Executive Dean for the University of North
Carolina School of Medicine as well as the Curnen Distinguished
Professor in the Department of Pediatrics. Dr. Burks heads a research
team whose work centers on the molecular identification of the allergens
in specific foods, a better understanding of the mechanism of adverse
food reactions, and the development of treatment for food allergy in
pre-clinical and clinical studies. He and his colleagues have several
ongoing clinical studies with different types of mucosal immunotherapy.
Dr. Burks is also a principal investigator for the Consortium of Food
Allergy Research (CoFAR), which was established in July 2005 by the
National Institute of Allergy and Infectious Diseases (NIAID) to conduct
both observational and clinical studies to answer questions related to
food allergies. Dr. Burks earned his medical degree at the University of
Arkansas for Medical Sciences, then completed a pediatric residency at
the Arkansas Children’s Hospital and a fellowship in allergy and
immunology at Duke University Medical Center. Dr. Burks is a past Chair
and member of the NIH Hypersensitivity, Autoimmune, and Immune-mediated
Diseases study section and is Past President of the American Academy of
Allergy, Asthma and Immunology, where he served from 2012 to 2013.

Thomas B. Casale, M.D., is a Professor of Medicine and Pediatrics at the
College of Medicine at the University of South Florida in Tampa,
Florida. Dr. Casale’s clinical and basic research interests are directed
toward determination and treatment of the pathophysiologic mechanisms
involved in asthma and allergic diseases. He is currently the director
of clinical and translational research and is actively involved in
examining immunomodulators for the treatment of inflammatory disorders.
He is also very active in the development of educational programs in
allergy and immunology for local, national and international meetings.
Dr. Casale earned his medical degree from the Rosalind Franklin
University of Medicine and Science, Chicago Medical School, then
completed his residency at Baylor College of Medicine and an
allergy/immunology fellowship at the National Institutes of Health. He
served as President of the American Academy of Allergy, Asthma and
Immunology from 2007 to 2008.

Jonathan Hourihane, M.D., is a Professor of Paediatrics and Child Health
at University College Cork in Ireland. His research interests focus on
the exploration of the link between skin barrier dysfunction and
systemic allergic disorders, threshold doses of food allergens,
immunomodulation of established allergic responses, prevention of
allergic sensitization, and evaluation of quality of life in food
allergic children. He is co-principal investigator for the BASELINE
birth cohort study, which is tracking more than 2,000 Irish children
from soon after conception over several years to study the effects of
intrauterine growth restriction, the incidence and prevalence of food
allergy and eczema in early childhood, and the incidence and effects of
maternal and infant vitamin D status on growth and health. He was
Founding Secretary of the Irish Association of Allergy and Immunology
and is Founding Chairman of the Irish Food Allergy Network. Dr.
Hourihane earned his Bachelor of Medicine (M.B.), Bachelor of Surgery
(B.Ch.), and Bachelor of Obstetrics (B.A.O.) degrees at Dublin
University, Trinity College and an M.D. from the University of

Stacie M. Jones, M.D., is a Professor of Pediatrics and Chief of Allergy
and Immunology at the University of Arkansas for Medical Sciences and
Arkansas Children’s Hospital. She is also a researcher at the Arkansas
Children’s Research Institute. Her research focuses on both clinical and
translational investigation of food allergy and eosinophilic
gastrointestinal disorders, as well as on asthma and lung disease. Dr.
Jones is also a principal investigator for the Consortium of Food
Allergy Research (CoFAR), which was established in July 2005 by the
National Institute of Allergy and Infectious Diseases (NIAID) to conduct
both observational and clinical studies to answer questions related to
food allergies. Dr. Jones earned her medical degree at the University of
Arkansas for Medical Sciences and completed her pediatrics residency
there and at Arkansas Children’s Hospital, followed by a fellowship in
Pediatric Allergy and Immunology at Johns Hopkins Hospital.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for life-threatening food allergies. The
company’s Characterized Oral Desensitization ImmunoTherapy
(CODIT™) approach is intended to achieve meaningful levels of protection
by desensitizing patients with defined, precise amounts of key
allergens. Aimmune’s first investigational product using CODIT™, AR101
for the treatment of peanut allergy, has received the FDA’s Breakthrough
Therapy Designation for the desensitization of peanut-allergic patients
4-17 years of age and is currently being evaluated in Phase 3 clinical
trials in ages 4-55. AR101 is a characterized, regulated, oral
biological drug product containing the protein profile found in peanuts.
For more information, please see

Forward-Looking Statements

Statements contained in this press release regarding matters that are
not historical facts are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding: Aimmune’s expectations for the its Scientific
Advisory Board; Aimmune’s expectations for its Phase 3 trials of AR101,
including PALISADE, RAMSES and ARTEMIS; Aimmune’s expectations regarding
the potential benefits of AR101; and Aimmune’s expectations regarding
potential applications of the CODIT™ approach to treating
life-threatening food allergies. Risks and uncertainties that contribute
to the uncertain nature of the forward-looking statements include: the
expectation that Aimmune will need additional funds to finance its
operations; the company’s ability to initiate and/or complete clinical
trials; the unpredictability of the regulatory process; the possibility
that Aimmune’s clinical trials will not be successful; Aimmune’s
dependence on the success of AR101; the company’s reliance on third
parties for the manufacture of the company’s product candidates;
possible regulatory developments in the United States and foreign
countries; and the company’s ability to attract and retain senior
management personnel. These and other risks and uncertainties are
described more fully in Aimmune’s most recent filings with the
Securities and Exchange Commission, including its Annual Report on Form
10-K for the year ended 2015 and Quarterly Report on Form 10-Q for the
quarter ended September 30, 2016. All forward-looking statements
contained in this press release speak only as of the date on which they
were made. Aimmune undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the date on
which they were made.

This press release concerns a product that is under clinical
investigation and that has not yet been approved for marketing by the
U.S. Food and Drug Administration (FDA) or the European Medicines Agency
(EMA). It is currently limited to investigational use, and no
representation is made as to its safety or effectiveness for the
purposes for which it is being investigated.


Aimmune Therapeutics, Inc.
Laura Hansen, Ph.D.,
Yao, 650-351-6479